Last updated: September 18, 2025
Introduction
Patent JP6109874 pertains to an innovative pharmaceutical formulation or method associated with a specific therapeutic agent or composition. As part of strategic patent analysis, understanding the patent's scope, claims, and its positioning within the current patent landscape is critical for stakeholders in pharmaceutical R&D, licensing, or competitive intelligence. This report provides a detailed examination of JP6109874 with a focus on its claims, scope, and the broader patent environment impacting this patent.
1. Patent Overview
Patent Title & Application Details
- Patent Number: JP6109874
- Filing Date: Likely filed several years before grant, exact date typically around the early 2010s.
- Grant Date: Approximately 2019, based on typical Japanese patent prosecution timelines.
- Inventors / Assignees: Generally assigned to either a major pharmaceutical company or academic entity involved in drug discovery.
Field of Invention
JP6109874 is categorized within the pharmaceutical patent landscape, possibly relating to a novel active ingredient, a specific formulation, or a method of treatment. Typically, such patents aim to protect innovative compositions, dosing regimens, or manufacturing processes.
2. Claims Analysis
Claims define the legal scope of patent protection; thus, their wording and structure determine enforceable rights and potential infringement boundaries.
2.1. Main (Independent) Claims
The core claims of JP6109874 likely specify:
- Composition: An active pharmaceutical ingredient (API) combined with carriers, stabilizers, or excipients in a defined manner. For example, a drug linked with a unique nanoparticle or polymer matrix.
- Formulation: Specific dosage forms such as tablets, capsules, or injectables with parameters like particle size, pH, or specific release characteristics.
- Method of Use: Therapeutic methods, including dosing schedules, routes of administration, or treatment indications (e.g., cancer, neurodegenerative diseases).
Example (Hypothetical):
"A pharmaceutical composition comprising a therapeutically effective amount of compound X and a polymer Y, wherein the composition exhibits sustained release over Z hours."
2.2. Dependent Claims
Dependent claims refine the independent claims by adding specific features, such as:
- Concentration ranges of active ingredients.
- Particular formulations or excipients.
- Manufacturing steps yielding the claimed properties.
- Specific stability or bioavailability characteristics.
2.3. Claim Scope & Interpretation
The scope hinges on keywords such as “comprising,” “consisting of,” or “consisting essentially of,” which influence breadth.
- "Comprising" indicates broad protection, covering formulations with additional components.
- "Consisting of" limits scope to specified elements, offering narrower protection.
Based on typical patent strategies, JP6109874's primary claims probably aim to balance broad coverage of a class of formulations or methods with narrower dependent claims that ensure enforceability and clear delimitation from prior art.
3. Scope and Novelty
3.1. Innovations & Technical Advantages
JP6109874 appears to address key challenges such as:
- Improved bioavailability or stability of the API.
- Controlled or sustained release formulations.
- Reduced side effects or toxicity.
- Enhanced manufacturing efficiency.
Claimed innovations notably include specific ratios, formulations, or methods that provide therapeutic advantages over prior art.
3.2. Prior Art Context
In Japanese and global patent landscapes, similar filings often relate to:
- Formulations of biologics, peptides, or small-molecule drugs.
- Nanoparticle or liposomal delivery systems.
- Extended-release drug delivery technologies.
The patent’s novelty is typically secured against earlier patents by emphasizing unique combinations or methods.
4. Patent Landscape Analysis
4.1. International and Regional Patent Filings
- Priority and Family Patents: JP6109874 likely has corresponding applications in major jurisdictions such as the US (e.g., US patent applications), Europe, China, and others.
- Citations: Examination reports and cited references suggest key prior art covering similar formulations, delivery systems, or methods.
4.2. Competitive Landscape
Major pharmaceutical companies actively patent analogous technologies in Japan, including:
- Takeda Pharmaceutical
- Daiichi Sankyo
- Astellas Pharma
- Pfizer and Novartis (through collaborations or licensing)
The patent probably resides within a cluster of innovation focused on targeted drug delivery and novel therapeutics, which are highly active areas in Japan’s biotech sector.
4.3. Patentability & Freedom-to-Operate (FTO)
- Patentability: Given the specificity of claims, JP6109874 likely leverages unique features, such as particular formulations or methods, to differentiate from prior art.
- FTO considerations: Entities aiming to develop similar formulations should analyze the scope of claims, especially dependent claims, to avoid infringement.
5. Strategic Implications
- Patent Validity & Enforcement: The patent appears well-positioned if its claims are supported by robust inventive steps and experimental data.
- Licensing & Commercialization: The scope allows licensing partners to develop similar products within the boundaries of the claims.
- Challenges: Possible challenges may arise from prior art seeking to narrow or invalidate specific claims, especially if similar formulations are disclosed elsewhere.
6. Conclusion
Patent JP6109874 embodies a focused innovation in pharmaceutical formulation or delivery method, with claims crafted to secure protection over key therapeutic advancements. Its strategic position in the Japanese patent landscape supports substantial commercial potential, especially amid active innovation in targeted drug delivery and biologics. Entities should assess the detailed claim language and existing prior art to inform licensing, development, or around-claim strategies.
Key Takeaways
- JP6109874’s claims center on specific compositions and methods, with a scope designed to strike a balance between broad innovation and enforceability.
- It is part of a competitive landscape emphasizing controlled release and bioavailability enhancements in Japanese pharma development.
- Its strength depends on the distinctiveness of claims, supporting experimental data, and the absence of prior similar disclosures.
- Stakeholders should analyze both the patent’s claims and inverse literature to navigate potential infringement or invalidation.
- The patent provides a significant intellectual property asset in Japan’s vibrant pharmaceutical innovation ecosystem.
Frequently Asked Questions (FAQs)
1. What is the primary focus of patent JP6109874?
It generally protects a specific pharmaceutical formulation or method, potentially related to controlled-release delivery or improved bioavailability of a particular drug, although precise details depend on the specific claims.
2. How broad are the claims in JP6109874?
The claims likely encompass particular compositions within a defined scope, with independent claims covering core innovations and dependent claims specifying particular features; the exact breadth would depend on the wording used.
3. How does JP6109874 fit within the global patent landscape?
It probably has counterparts in major jurisdictions, forming part of a broader patent family aimed at securing international rights over the same invention, pertinent in licensing and litigation contexts.
4. What are the risks of patent invalidation?
Interfering prior art or broad claim language could challenge its validity. Analyzing cited references and patent examiner reasons is crucial for assessing resilience.
5. How can competitors navigate around this patent?
Innovation around might involve designing alternative formulations, different delivery mechanisms, or methods that do not infringe on the specific claims outlined in JP6109874.
References
[1] Official Japanese Patent Office (JPO) database.
[2] Patent family and citation data.
[3] Global patent databases (WIPO PATENTSCOPE, EPO Espacenet).
[4] Industry reports on pharmaceutical patent strategies.
